Viking Therapeutics ($VKTX) has experienced a dramatic decline in its stock price, dropping from $80 to $30 over a three-month period. The company's recent oral data update led to a significant loss of investor confidence, with the stock previously reaching a peak of over $90. Analysts suggest that the CEO should focus on clearer communication with investors, particularly regarding potential partnerships and upcoming deadlines. The company is expected to provide further updates and catalysts during its earnings call in early February. In related news, P180 has acquired a 65% majority stake in Vince Holding Corp ($VNCE) from Sun Capital, which has resulted in a pre-market surge of 55.3% for Vince's stock. Brendan Hoffman will return as CEO, aiming to leverage P180's focus on luxury apparel growth and reduce Vince's debt by $27 million.